Chee Kong Choo Acquires 112,000 Shares of CytoMed Therapeutics (NASDAQ:GDTC) Stock

CytoMed Therapeutics Limited (NASDAQ:GDTC) Director Chee Kong Choo bought 112,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $1.15 per share, for a total transaction of $128,800.00. Following the completion of the transaction, the director directly owned 430,324 shares of the company’s stock, valued at $494,872.60. This represents a 35.18% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

CytoMed Therapeutics Price Performance

NASDAQ GDTC opened at $1.12 on Wednesday. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.06. The business’s fifty day moving average is $1.04 and its 200 day moving average is $1.15. CytoMed Therapeutics Limited has a fifty-two week low of $0.68 and a fifty-two week high of $3.68.

CytoMed Therapeutics (NASDAQ:GDTC) last released its earnings results on Sunday, February 15th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Friday, April 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, CytoMed Therapeutics presently has a consensus rating of “Sell”.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.